

Biological psychiatry.  
v. 63 no. 7, suppl. (Apr 1 2008)  
General Collection  
W1 B175et.  
2008-04-08 08:29:11

# Biological Psychiatry

Volume 63, Number 7S

April 1, 2008

Supplement



PROPERTY OF THE  
NATIONAL  
LIBRARY OF  
MEDICINE

ISSN 0006-3223

[www.sobn.org/journal](http://www.sobn.org/journal)

**DOCKET  
ALARM**

Find authenticated cour

Mylan v. Janssen (IPR2020-00440) Ex. 1041, p. 001



**Customer Service (orders, claims, online, change of address):** Elsevier Periodicals Department, 6277 Sea Harbor Drive, Orlando, FL 32887-4800. Tel: (800) 654-2452 (U.S. and Canada); (407) 563-6020 (outside U.S. and Canada). Fax: (800) 225-4030 (U.S. and Canada); (407) 363-9661 (outside U.S. and Canada). E-mail: JournalsCustomerService-usa@elsevier.com. Address changes must be submitted four weeks in advance.


**Yearly subscription rates:** United States and possessions: Individual: USD 983; Institution: USD 2523; Student/Resident: USD 200. Same for all other countries (prices include airspeed delivery). To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the signature of program/residency coordinator on institution letterhead. Orders will be billed at the individual rate until proof of status is received. Current prices are in effect for back volumes and back issues.

**Single issue purchase:** 94 USD. Please contact Customer Service at the Elsevier Periodicals Department, 6277 Sea Harbor Drive, Orlando, FL 32887-4800. Tel: (800) 654-2452 (U.S. and Canada); (407) 345-4000 (outside U.S. and Canada). E-mail: elspcs@elsevier.com.

**Advertising information:** Advertising orders and inquiries can be sent to: **United States, Canada, and South America,** Inez Herrero at Elsevier, 360 Park Avenue South, New York, NY 10010, USA; Tel: (212) 633-3122; Fax (212) 633-3820. Classified advertising orders and inquiries can be sent to Simone Imbert, Elsevier Inc., 360 Park Avenue South, New York, NY 10010, USA; Tel: (212) 462-1908. **Europe and the rest of the world:** Julie Toop; Tel: +44 (0) 1865-843016; Fax: +44 (0) 1865-843976; E-mail: media@elsevier.com.

**Author inquiries.** For inquiries relating to the submission of articles, please see Information for Authors in this issue or contact the Journal's Editorial Office in Dallas, TX. Please also visit [www.elsevier.com/authors](http://www.elsevier.com/authors) which provides the facility to track accepted articles and set up e-mail alerts to inform you of when an article's status has changed, as well as detailed artwork guidelines, copyright information, frequently asked questions, and more. Contact details for questions arising after acceptance of an article, especially those relating to proofs, are provided after registration of an article for publication.

**Reprints.** For queries about author offprints, e-mail: [authorsupport@elsevier.com](mailto:authorsupport@elsevier.com). To order 100 or more reprints for educational, commercial, or promotional use, contact the Commercial Reprints Department, Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710. Fax: (212) 462-1935; e-mail [reprints@elsevier.com](mailto:reprints@elsevier.com). Reprints of single articles available online may be obtained by purchasing Pay-Per-View access for \$32 per article on the journal website, <http://www.sobp.org/journal>.

 The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).

© 2008 Society of Biological Psychiatry. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by the Society of Biological Psychiatry, and the following terms and conditions apply to their use:

**Photocopying.** Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

**Permissions** may be sought directly from Elsevier's Global Rights Department in Oxford, UK: phone (215) 239-3804 or +44 (0)1865 843830, fax +44 (0)1865 853333, e-mail [healthpermissions@elsevier.com](mailto:healthpermissions@elsevier.com). Requests may also be completed online via the Elsevier homepage (<http://www.elsevier.com/permissions>). In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 750-8400, fax: (978) 750-4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 20 7631 5555; fax: (+44) 20 7631 5500. Other countries may have a local reprographic rights agency for payments.

**Derivative Works.** Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations.

**Electronic Storage or Usage.** Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Rights Department, at the fax and e-mail addresses noted above.

**Notice.** No responsibility is assumed by the publisher or by the Society of Biological Psychiatry for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

*Biological Psychiatry is cited in Beck Medical Information, Biological Abstracts, CABS/Current Awareness in Biological Sciences, Chemical Abstracts, Current Contents, Excerpta Medica, Index Medicus, Inpharma, LMS Alerts Online (DataStar), Mental Health Abstracts, Psychological Abstracts, Reactions, Referativnyi Zhurnal, Reference Update, Science Citation Index, and Selected List of Tables of Contents of Psychiatric Periodicals.*

- Johns, J. M. 281  
 Johnson, A. Kim. **115**  
 Johnson, C. 262  
 Johnson, J. 22  
 Johnson, K. 641  
 Johnson, K. A. 443, **510**, 647, **932**  
 Johnson, L. L. 376  
 Johnstone, E. C. 488  
 Johnstone, T. **147**  
 Jokinen, J. **922**  
 Jollant, F. **923**  
 Jonak, G. 389  
 Jones, E. G. 927  
 Jones, H. 561  
 Jones, M. 548  
 Joober, R. 765, 790, 848, 849, 885  
 Josephson, M. 476  
 Jovanovic, T. **550**  
 Joyce, E. M. 152  
 Jucaite, A. 321  
 Jungerman, F. 55, 56  
 Jurjus, G. 653  
 Kabir, A. 146  
 Kaddurah-Daouk, R. 272, **453**  
 Kaffenberger, T. 162  
 Kagedal, M. 321  
 Kahn, A. S. **645**  
 Kahn, J. 477  
 Kahn, R. S. 737, **744**  
 Kaiser, J. 763  
 Kalali, A. H. 766  
 Kalas, C. 68, 615  
 Kalidindi, S. 71  
 Kalin, N. H. 147, 177, 180  
 Kalisch, R. **144**  
 Kalmar, J. H. 119, 142, 437, 487, **579**  
 Kaluzhny, P. 690  
 Kamath, V. **375**, 387  
 Kanba, S. 801, 814, 822  
 Kane, J. M. 27, 244, 382, 875, 911, 913  
 Kanellopoulou, I. **804**  
 Kang, C. 97  
 Kang, H. 232  
 Kansaku, K. 356  
 Kantamneni, A. 84  
 Kantrowitz, J. T. **902**  
 Kapas, M. 905  
 Kaplan, B. B. **150**  
 Kaplan, J. 534  
 Kaprio, J. 81  
 Kapur, S. 39, 484, 717, 888  
 Karayal, O. 898  
 Karlsgodt, K. H. **805**  
 Karlsson, P. 321  
 Karlsson, R. **191**  
 Karmacharya, R. **316**  
 Karp, J. 575  
 Karpf, R. 119  
 Karpyak, V. M. **525**  
 Karry, R. 256  
 Kartan, S. 388, 850  
 Kasahara, E. **296**, 35  
 Kasai, K. 857  
 Kasserman, S. 119, 557  
 Kato, T. 419  
 Katz, D. A. 39  
 Katz, E. R. 725  
 Katz, N. S. **317**  
 Katzman, M. **435**  
 Kaufman, J. 15  
 Kaushik, S. **806**, 906  
 Kawakubo, Y. 857  
 Kawashima, T. **867**  
 Kaye, W. H. 67, 468, 469, 774  
 Kayser, J. **239**, 242  
 Keefe, R. **363**  
 Keegan, K. A. **291**  
 Keenan, T. 390  
 Keener, M. T. **171**  
 Keilp, J. G. 105  
 Keller, K. E. 166  
 Keller, K. L. 606  
 Kelley, M. E. 644  
 Kelly, A. 348  
 Kelly, A. M. 119, 159, 517  
 Kelly, C. 20  
 Kelly, C. 947  
 Kelly, M. 834  
 Kelly, M. P. 17  
 Kelly, S. P. 843  
 Kelsoe, J. R. 247, 476  
 Kem, W. R. 376  
 Kema, I. P. 944  
 Kemether, E. 897  
 Kempf, L. 234, **852**  
 Kenna, H. 48  
 Kennedy, J. L., 51, **503**, 727, 861, 864  
 Kennedy, S. E. 353  
 Kennedy, S. H. **646**  
 Kennel, C. 363  
 Keshavan, M. S. 93, 117, 272, 377, **378**, 379, 613, 800, 825  
 Kessler, R. 33, 230, 682  
 Ketter, T. A. 567, 606  
 Khadivi, A. 875  
 Khairova, R. A. **268**  
 Khan, A. 806, 811, 906  
 Khan, S. 385, 834  
 Khan, U. **807**  
 Khanna, A. 345  
 Khine, T. T. 800, 825  
 Kiesepää, T. 81  
 Kiltz, J. D. 688  
 Kim, H. 175  
 Kim, J. 525  
 Kim, P. 232  
 Kim, S. 846  
 Kim, Y. 547  
 Kimak, M. A. 462, 539  
 Kimhy, D. 385, 834  
 King, A. P. **551**  
 King, E. **221**, 827  
 King, N. 51  
 King, S. 848  
 King, T. 189  
 Kinnally, E. L. 339  
 Kinon, B. J. 888, 889  
 Kipp, H. 613  
 Kippenhan, J. S. 212, **222**, 252  
 Kirbas, C. 870  
 Kirov, G. 383  
 Kish, S. J. 101, 50, 717  
 Kjartansson, Ó. 52  
 Klabunde, M. 468  
 Kleber, R. 282  
 Klein, C. 357  
 Klein, C. R. 49, 170, 605  
 Klein, E. 184, 267  
 Klein, R. G. **417**  
 Kleinhaus, K. **407**, 853  
 Kleinman, J. E. 297, 475  
 Klempan, T. A. **259**  
 Kling, M. A. 329  
 Kloiber, S. 250  
 Klossika, I. 401, 403  
 Klumpp, H. 544  
 Klunder, A. D. 350  
 Kmiecik, L. 99  
 Knauer, C. S. **269**  
 Knop, J. 394, 53  
 Ko, D. 204, 205, 206  
 Kobeissy, F. H. **273**  
 Koch, J. K. 598, 818  
 Kochetkova, A. 497  
 Koenigsberg, H. W. **145**, **413**, 414, **473**, 505  
 Kogan, J. **116**  
 Kohler, C. **386**, 785, 787, 809, **868**  
 Kohn, P. D. 210, 212, 221, 227, 252, 254, 794  
 Kohn, P. F. 279  
 Kolachana, B. 227, 252, 254, 794, 858  
 Kolden, G. P. 147  
 Kolivakis, T. 646  
 Kollack-Walker, S. 888, 889  
 Kollins, S. H. **771**  
 Kolochana, B. 852  
 Kondo, H. 208  
 Kondo, T. 802  
 Kondziolka, D. 930  
 Konradi, C. 576  
 Koo, M. 360  
 Kopecek, M. 350  
 Kopecek, M. **580**, **581**, **87**  
 Koran, L. M. 532  
 Korf, J. 944  
 Korth, C. **3**  
 Kose, S. **443**, 510, 641, **647**  
 Kosik-Gonzalez, C. 766, 887  
 Koury, M. 1  
 Kozaric-Kovacic, D. 550  
 Kozel, F. 443, 510  
 Krain, A. L. 159  
 Kramer, E. 645  
 Kramer, M. 908  
 Kramer, W. E. 26  
 Kraus, M. 363  
 Kraut, M. A. 154  
 Kreher, D. A. 368  
 Kremen, W. S. 497  
 Krieg, J. 649  
 Krieg, J. C. 444, 628, 649  
 Kring, A. M. 837  
 Kronfeld-Scor, N. 186



**Methods:** Metabolic and cardiovascular data from 357 chronically ill (38.3 + 10.05 years old, 251 Male, 70.4% African-American) schizophrenia patients who were screened for participation in clinical trials from 1998-2007 (80.2% on atypical antipsychotics, 12.3% on typical antipsychotics, 7.5% untreated) were compared to a sample of 2,531 non-schizophrenic age-matched controls from the 2003-2004 Center for Disease Control and Prevention's **National Health and Nutrition Examination Survey** (NHANES) on measures including fasting blood sugars and lipids, BMI, and blood pressure.

**Results:** 29.1% of patients were overweight (BMI>25) and 37.8% were obese (BMI>30). Fasting lipids, cholesterol and triglycerides were elevated in 39.3% and 40.5% of patients respectively. Elevations in fasting blood sugar (FBS >110mg/dl) were found in 16.7% of patients with 7.6% having diabetes (FBS >126mg/dl). 15.5% were hypertensive (diastolic BP >85mmHg), and 54.5% had abnormal ECGs. 34% had metabolic syndrome (n=189). There were no differences across variables when compared to the age-matched NHANES controls. No association with either typical or atypical neuroleptic treatment was found based on  $\chi^2$  tests of differences.

**Conclusions:** Lack of differences with recent NHANES control data and lack of association with neuroleptic therapy suggests that other factors besides neuroleptic treatment (eg. diet, lifestyle) play a role in metabolic and cardiovascular abnormalities found in schizophrenia patients.

### 908. Efficacy and Tolerability of Paliperidone Palmitate: 9-week, Placebo-Controlled Study in Schizophrenia Patients

Michelle Kramer<sup>1</sup>, Robert E. Litman<sup>2</sup>, Rosanne Lane<sup>1</sup>, Pilar Lim<sup>1</sup>, David Hough<sup>1</sup>, Marielle Eerdeken<sup>3</sup>

<sup>1</sup>Johnson & Johnson Pharmaceutical Research & Development, Titusville, NJ, <sup>2</sup>CBH Health, LLC, Rockville, MD, <sup>3</sup>Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium

**Background:** This study evaluated the efficacy and safety of paliperidone palmitate, a long-acting injectable agent, in the treatment of schizophrenia patients.

**Methods:** A 9-week, double-blind, placebo-controlled study randomized patients to placebo or paliperidone palmitate 50 or 100 mg eq. on Days 1, 8 and 36 (without oral supplementation). Efficacy and tolerability were evaluated via changes in mean Positive and Negative Syndrome Scale (PANSS) total scores and adverse event (AE) reporting, respectively.

**Results:** The intention-to-treat population included 197 patients (male=62%, mean±standard deviation [SD] age=39.3±10.3y; placebo N=66; paliperidone palmitate 50 mg eq. N=63; paliperidone palmitate 100 mg eq. N=68). Mean±SD PANSS total scores significantly improved ( $p \leq 0.001$ ) from baseline (87.0±12.5) to end point for paliperidone palmitate 50 mg eq. (-5.2±21.5) and 100 mg eq. (-7.8±19.4) versus placebo (+6.2±18.3), with significant improvements observed from Day 8. Responder rates ( $\geq 30\%$  improvement in PANSS total score at end point) were significantly greater in both paliperidone palmitate groups versus placebo ( $p \leq 0.007$ ). AEs occurring  $\geq 3\%$  more in either paliperidone palmitate group versus placebo (safety population, N=247) were insomnia, schizophrenia, restlessness, sedation, extrapyramidal disorder, hypertonia, attention disturbance, electrocardiogram abnormal, constipation, myalgia, asthenia and vertigo. Extrapyramidal symptoms-AE rates were comparable for paliperidone palmitate and placebo, with the exception of parkinsonism (7% and 1%, respectively). Serious AEs in  $\geq 1$  patient (any group) were schizophrenia and psychotic disorder. Injections were generally well tolerated. No deaths occurred.

**Conclusions:** Paliperidone palmitate (50 and 100 mg eq. doses) is effective and well tolerated in acute symptomatic schizophrenia.

Supported by Johnson & Johnson Pharmaceutical Services, LLC., and Johnson & Johnson Pharmaceutical Research & Development

### 909. Pharmacokinetics (PK) of Multiple Doses of Olanzapine Long Acting Injection (OLAI), an Intramuscular (IM) Depot Formulation of Olanzapine (OLZ), in Stabilized Patients with Schizophrenia

Darcie Kurtz, Richard Bergstrom, David P. McDonnell, Malcolm Mitchell

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN

**Background:** Olanzapine pamoate is a long-acting depot formulation of OLZ that is an effective treatment for patients who benefit from the advantages of a depot. It has not yet been approved.

**Methods:** Schizophrenic patients stabilized on daily oral OLZ received multiple OLAI injections at doses of 100, 150, 160, 200, and 300 mg/2 weeks and 200, 255, 300, and 405 mg/4 weeks for 24 weeks. After each injection, serial plasma OLZ concentration samples were collected. PK were characterized using non-compartmental methods.

**Results:** The injections were well tolerated overall. Absorption-limited PK were observed. Plasma OLZ concentrations were sustained throughout both the 2- and 4-week injection intervals. On average, OLZ concentrations accumulate 2- to 3-fold upon multiple dosing and reach steady-state conditions after about 3 months of dosing. Peak-to-trough fluctuation in OLZ concentrations averages 51% for the 2-week injection interval and 75% for the 4-week interval. Maximum concentration and area under the concentration versus time curve for OLZ were proportionate to OLAI dose. Relative to oral OLZ ( $t_{max} = 6$  hr,  $t_{1/2} = 29$  hr), the time of peak concentration following OLAI was 4 days and the half-life was approximately 26 days. The average steady-state concentrations sustained by OLAI correspond to those maintained by daily OLZ in the dosage range of 5-20 mg/day.

**Conclusions:** IM administration of OLAI is well tolerated and provides steady-state concentrations that are sustained over 4 weeks and are comparable to oral treatment.

Supported by Eli Lilly and Company

### 910. Relapse Prevention: Risperidone Long-Acting Injectable Vs Quetiapine or Aripiprazole

Rossella Medori

Medical Affairs, Janssen-Cilag, Beerse, Belgium

**Background:** To investigate if risperidone long-acting injectable (RLAI) provides better efficacy maintenance over 2 years, as measured by the time to relapse, in comparison to the oral atypical antipsychotic quetiapine or aripiprazole.

**Methods:** Open-label, active-controlled, multicenter, randomized, 2-year trial of RLAI versus oral quetiapine or aripiprazole in 731 patients with schizophrenia currently treated with oral risperidone, olanzapine or conventional neuroleptics. Symptomatically stable patients on a stable dose of an antipsychotic for  $\geq 4$  weeks were enrolled. Primary efficacy evaluation was time to relapse. Secondary efficacy evaluations included: Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Severity (CGI-S), Montgomery-Asberg Depression Rating Scale (MADRS) and Social and Occupational Functioning Assessment Scale (SOFAS). Safety evaluations included adverse events monitoring, Extrapyramidal Symptom Rating Scale (ESRS), clinical laboratory tests and vital signs.

**Results:** 808 subjects were screened and 731 (58.3% male, mean age 41.5 [SD:12.8] years) were randomized to treatment. Mean time since first onset was 13.9 (SD:11.2) years; mean time since first treatment was 12.5 (SD:10.7) years. At baseline 34.4% of subjects fulfilled the remission severity criteria. Reasons for switching (>1 allowed) included: insufficient efficacy; negative (29.8%), positive (14.1%), and general symptoms (21.1%) and adverse events (18.9%). Baseline scores were: PANSS: 73.0 (SD:21.8), CGI-S: 3.7 (SD:1.0).